Simcere Pharmaceutical Group Past Earnings Performance
Past criteria checks 3/6
Simcere Pharmaceutical Group's earnings have been declining at an average annual rate of -8.7%, while the Pharmaceuticals industry saw earnings growing at 4.6% annually. Revenues have been growing at an average rate of 9.3% per year. Simcere Pharmaceutical Group's return on equity is 10.4%, and it has net margins of 11%.
Key information
-8.7%
Earnings growth rate
-10.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.6% |
| Revenue growth rate | 9.3% |
| Return on equity | 10.4% |
| Net Margin | 11.0% |
| Last Earnings Update | 31 Dec 2024 |
Recent past performance updates
We Like Simcere Pharmaceutical Group's (HKG:2096) Earnings For More Than Just Statutory Profit
May 06
Recent updates
We Like Simcere Pharmaceutical Group's (HKG:2096) Earnings For More Than Just Statutory Profit
May 06Simcere Pharmaceutical Group Limited's (HKG:2096) Price In Tune With Revenues
Mar 06Simcere Pharmaceutical Group Limited's (HKG:2096) P/S Still Appears To Be Reasonable
Nov 21Simcere Pharmaceutical Group Limited (HKG:2096) Not Lagging Market On Growth Or Pricing
Jul 29Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems
May 01Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market
Dec 29Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates
Aug 28Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%?
Jun 03Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically
Apr 06Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096)
Jan 10Revenue & Expenses Breakdown
How Simcere Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 24 | 6,635 | 733 | 3,030 | 1,410 |
| 30 Sep 24 | 6,487 | -185 | 2,883 | 1,382 |
| 30 Jun 24 | 6,340 | -1,102 | 2,735 | 1,353 |
| 31 Mar 24 | 6,474 | -194 | 2,795 | 1,458 |
| 31 Dec 23 | 6,608 | 715 | 2,855 | 1,563 |
| 30 Sep 23 | 6,807 | 1,928 | 2,998 | 1,708 |
| 30 Jun 23 | 7,006 | 3,141 | 3,141 | 1,853 |
| 31 Mar 23 | 6,665 | 2,036 | 2,988 | 1,790 |
| 31 Dec 22 | 6,324 | 931 | 2,835 | 1,728 |
| 30 Sep 22 | 5,952 | 972 | 2,709 | 1,585 |
| 30 Jun 22 | 5,579 | 1,013 | 2,584 | 1,441 |
| 31 Mar 22 | 5,290 | 1,260 | 2,501 | 1,429 |
| 31 Dec 21 | 5,000 | 1,507 | 2,419 | 1,417 |
| 30 Sep 21 | 4,852 | 1,274 | 2,306 | 1,366 |
| 30 Jun 21 | 4,703 | 1,042 | 2,193 | 1,315 |
| 31 Mar 21 | 4,606 | 856 | 2,088 | 1,228 |
| 31 Dec 20 | 4,509 | 670 | 1,982 | 1,142 |
| 30 Sep 20 | 4,528 | 699 | 1,990 | 1,030 |
| 30 Jun 20 | 4,548 | 728 | 1,997 | 918 |
| 31 Mar 20 | 4,792 | 866 | 2,183 | 817 |
| 31 Dec 19 | 5,037 | 1,004 | 2,368 | 716 |
| 31 Dec 18 | 4,514 | 734 | 2,512 | 447 |
| 31 Dec 17 | 3,868 | 350 | 2,433 | 212 |
Quality Earnings: 2096 has a large one-off loss of CN¥264.4M impacting its last 12 months of financial results to 31st December, 2024.
Growing Profit Margin: 2096's current net profit margins (11%) are higher than last year (10.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2096's earnings have declined by 8.7% per year over the past 5 years.
Accelerating Growth: 2096's earnings growth over the past year (2.6%) exceeds its 5-year average (-8.7% per year).
Earnings vs Industry: 2096 earnings growth over the past year (2.6%) exceeded the Pharmaceuticals industry -9.6%.
Return on Equity
High ROE: 2096's Return on Equity (10.4%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/06 11:33 |
| End of Day Share Price | 2025/05/06 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Simcere Pharmaceutical Group Limited is covered by 17 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shaojing Tong | BofA Global Research |
| Bo Yu | China International Capital Corporation Limited |
| Shitong Han | Citic Securities Co., Ltd. |